Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (131-140 of 791) with videos related to

Pageof 80
Sort By:
Current Hematologic Malignancy Reports|April 29, 2010
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemiaRonan Swords, Yesid Alvarado, Jorge Cortes, et al.
The New England Journal of Medicine|April 26, 2013
Saving Medicare through patient-centered changes--the case of injectablesJeffrey S Farroni, Leonard Zwelling, Jorge Cortes, et al.
Seminars in Hematology|September 30, 2010
The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?Bing Z Carter, Duncan H Mak, Jorge Cortes, et al.
Current Hematologic Malignancy Reports|April 29, 2010
Tyrosine kinase inhibitors: the first decadeMeetu Agrawal, Ravin J Garg, Jorge Cortes, et al.
Hematology. American Society of Hematology. Education Program|November 26, 2002
Chronic myelogenous leukemiaBrian J Druker, Stephen G O'Brien, Jorge Cortes, et al.
Revista De Salud Publica (Bogota, Colombia)|August 24, 2006
[Anti-microbial resistance in intensive care units in Bogotá, Colombia, 2001-2003]Carlos Alvarez, Jorge Cortes, Alvaro Arango, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Important therapeutic targets in chronic myelogenous leukemiaHagop M Kantarjian, Francis Giles, Alfonso Quintás-Cardama, et al.
Haematologica|September 6, 2015
Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitorDavid Sanford, Hagop Kantarjian, Jeffrey Skinner, et al.
Expert Review of Hematology|February 9, 2016
Omacetaxine Mepesuccinate for Chronic Myeloid LeukemiaYasmin Rosshandler, Ann Q Shen, Jorge Cortes, et al.
Idrugs : the Investigational Drugs Journal|July 21, 2007
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyondElias Jabbour, Jorge Cortes, Francis Giles, et al.
Pageof 80

Showing results (131-140 of 791) with videos related to

Sort By:
Pageof 80
Current Hematologic Malignancy Reports|April 29, 2010
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemiaRonan Swords, Yesid Alvarado, Jorge Cortes, et al.
The New England Journal of Medicine|April 26, 2013
Saving Medicare through patient-centered changes--the case of injectablesJeffrey S Farroni, Leonard Zwelling, Jorge Cortes, et al.
Seminars in Hematology|September 30, 2010
The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?Bing Z Carter, Duncan H Mak, Jorge Cortes, et al.
Current Hematologic Malignancy Reports|April 29, 2010
Tyrosine kinase inhibitors: the first decadeMeetu Agrawal, Ravin J Garg, Jorge Cortes, et al.
Hematology. American Society of Hematology. Education Program|November 26, 2002
Chronic myelogenous leukemiaBrian J Druker, Stephen G O'Brien, Jorge Cortes, et al.
Revista De Salud Publica (Bogota, Colombia)|August 24, 2006
[Anti-microbial resistance in intensive care units in Bogotá, Colombia, 2001-2003]Carlos Alvarez, Jorge Cortes, Alvaro Arango, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Important therapeutic targets in chronic myelogenous leukemiaHagop M Kantarjian, Francis Giles, Alfonso Quintás-Cardama, et al.
Haematologica|September 6, 2015
Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitorDavid Sanford, Hagop Kantarjian, Jeffrey Skinner, et al.
Expert Review of Hematology|February 9, 2016
Omacetaxine Mepesuccinate for Chronic Myeloid LeukemiaYasmin Rosshandler, Ann Q Shen, Jorge Cortes, et al.
Idrugs : the Investigational Drugs Journal|July 21, 2007
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyondElias Jabbour, Jorge Cortes, Francis Giles, et al.
Pageof 80